initi buy pt pipelin
upsid like come alzheim despit sma competit
neurosci focus compani grow biosimilar pipelin
believ risk/reward profil aducanumab fda approv despit
headwind sma believ spinraza valu near-term physician
patient take time get comfort safeti efficaci durabl
newer drug think biosimilar busi help grow
interest chines market biosimilar capit alloc
strategi samsung bioepi add upsid
thesi hing alzheim work see posit risk/reward
fda decis fv upside/downsid shot
goal aducanumab file earli data
assum probabl ad ww peak adjust sale
despit recent approv zolgensma potenti approv risdiplam
believ spinraza near-term still lead sma share spinraza
avail countri broad label kol note may
take time physician patient get comfort newer product
biosimilar appreci could add upsid growth
compound-annual-growth-rate street recent commerci right
biosimilar lucenti eylea combin ww sale
samsung bioepi add growth also gain commerci right
access china market anti-tnf biosimilar enbrel/remicade/humira
combin ww sale everi addit sale add
could off-set spinraza declin
believ tecfidera remain intact posit ipr feb tecfidera
goe gener could see fv
tauopathi al deep dive report page
model conserv model competit eros
spinraza versu street gener ms competit
valuat risk
pt deriv dcf assum ms sale declin
spinraza peak sale adjust ad
sale model dcf termin growth rate
discount rate instead matur biotech compani account
potenti commerci execut ad termin valu arriv
pt risk includ fda reject aducanumab increas sma
competit tecifdera gener
tr target
initi buy
page
page
pm summari initi buy pt
thesi hing alzheim work could first market disease-
modifi drug two shot goal aducanumab file earli phase
clariti ad final data cy see good risk/reward decis continu
believ higher dose need get brain titrat dose could mitig
aria- amyloid-rel imag abnorm edema assum probabl ad
conserv assum ww peak adjust sale
despit recent approv novarti novn-ch nr zolgensma potenti approv roch
rog-ch nr risdiplam like sma believ spinraza near-term still command
share sma market spinraza avail addit countri use across sma
type age group also believ take time physician patient get comfort
data recent approv product defer spinraza
market sever year
believ biosimilar portfolio underappreci could provid upsid growth compound-annual-growth-rate
consensu biib biosimilar pipelin continu grow
recent expans biosimilar lucenti eylea combin global sale
samsung bioepi privat addit gain commerci right access china
market anti-tnf biosimilar portfolio
believ tecfidera franchis remain intact believ ipr litig go favor
time
catalyst next month fda accept aducanumab bla earli
aducanumab adcomm like fda approv
page
modest sale growth spinraza
declin sale
modest sale growth spinraza
declin sale
spinraza declin sale start
adjust peak sale
sale alzheim
probabl ad
fda reject aducanumab bla file
increas competit risdiplam zolgensma sma
lose ipr tecfidera gener launch
page
confid ad come amyloid plaqu reduct clinic endpoint
believ higher dose aducanuamb would need achiev efficaci base
prior studi similar monoclon antibodi
prime phase studi aducanumab dose-depend respons endpoint
cdr-sb mmse highest benefit
prime phase lte studi month show continu reduct amyloid plaqu
prime also show reduct brain amyloid correl slow cognit declin
aria- tend occur earli cours treatment transient aria- reduc
dose titrat approach use carrier compar fixed-dos
studi drug toxic get much antibodi brain
therefor like unabl show efficaci
studi drug similar aducanumab also show dose respons
bi-weekli month effect
studi appear show threshold effect monthli effect
month
page
full contribut ad could add addit biosimilar pipelin could provid upsid
assum ms busi fairli stabl tecfidera franchis remain intact
biosimilar portfolio continu evolv grow could see upsid
addit market china
note give credit earli stage pipelin
probabl success
sotp pt
page
trade larg pharma
page
divcurr tickerntm mean ex-bmrn premium/discount mean ex-bmrn/ mean ex-bmrn/pharma strh factset valu multipleconsensu inc
fell trade narrow band
plan
bla file
earli
studi termin
page
biogen inc
aducanumab file help stock recoveri investor still skeptic
page
ytd road recoveri
page
strh factset valu biogen inc
could still good stock long-term investor consist beat guidanc
upper end revenu guidanc
lower end revenu guidanc
page
done good job beat bottom-lin well
upper end non-gaap ep guidanc
lower end non-gaap ep guidanc
page
model tp use dcf discount rate termin valu
model dcf termin growth rate discount rate account
potenti commerci execut ad termin valu arriv tp
page
downsid
phase final readout psp expect
phase studi cle/sl expect
ptab decis earli
phase data expect
phase data
ophthalmolog phase data expect
parkinson diseas phase data expect
valor phase data expect
potenti launch
page
page
investor highli skeptic fda approv despit support file base emerg engag
octob investor surpris news intend file approv
aducanumab alzheim diseas
view sever reason support view approv
support prime phase result dose-depend cdr-sb
month arm aducanumab better lower dose group
statist signific improv cdr-sb baselin one year
cdr-sb result aducanumab prime studi
compon adcom
also case regard plaqu reduct mmse mmse differ
placebo statist signific dose
page
also case regard amyloid plaqu reduct mmse
mmse differ placebo statist signific dose
prime plaqu reduct dose
mmse chang baselin prime variou dose
page
support think data support thesi
remind similar aducanumab select bind aggreg
endpoint use two phase aducanumab studi cdr-sb show
reduct bi-weekli dose took forward phase statist
signific p-valu
slow cognit declin cdr-sb month
page
acknowledg controversi howev think threshold effect support thesi
first highest dose enrol carrier arm placebo arm
creat imbal carrier kol believ could
rapid progressor literatur less clear
second controversi threshold effect investor understand mg/kg
twice month look good month
threshold effect seen across mani endpoint mmse chang
page
take look data whole support effect
even seen presenc cerebrospin fluid csf dose depend
increas support idea antibodi bind found csf
half-lif increas
would impact carrier statu bi-weekli arm statist
signific tau also declin top two dose tau thought
correl diseas sever
dose vs placebo bind
page
await final data confirmatori phase clarity-ad
follow discuss fda studi phase trial march
eisai nr announc would jointli run trial earli alzheim diseas
studi call clariti ad placebo-control double-blind parallel-group random
enrol patient either mild cognit impair due alzheim diseas ad
mild alzheim diseas dementia confirm amyloid patholog brain
addit studi ongoing/underway
phase open label extens studi on-going
secondari prevent studi studi underway start
page
clariti ad look bi-weekli believ aduca good read-through
clarity-ad studi patient random receiv either placebo
primari endpoint clinic dementia rating-sum box cdr-sb month treatment
chang clinic scale ad composit score adcom ad assess scale-cognit subscal
adas-cog key secondari endpoint along brain amyloid level measur amyloid
confirmatori phase follow phase studi patient earli ad data show
strong reduct amyloid-beta brain effect csf biomark neurodegener
phase studi bi-weekli top dose show deepest reduct adcom
time start month treatment slow cognit declin adcom
across time point versu placebo also slow cognit declin adas-
cogs reduct versu placebo
page
think investor assign valu alzheim next month
bapinezumab gantenerumab pave way aducanumab better
understand sampl size placebo respons analysi methodolog safeti event seen
base data seen aducanumab dose high enough shown posit
trend reduct plaqu clinic endpoint cognit declin biib/eisai learn
post-mortem analys bapi/g data
page
aducanumab phase engag emerg studi design
page
page
believ spinraza still preferenti competitor
spinraza year data physician patient familiar
data administr safety/efficaci profil accord doc check
spinraza two competitor novarti zolgensma roch risdiplam could meaning
impact beyond
includ key pushback kol check
zolgensma appeal given once-onli iv administr gene therapi howev
patient concern long-term safety/dur infant develop liver
pushback use zolgensma includ
access/cost price tag insur limit age administr label
less
dilut effect grow tissu
risdiplam oral formul offer conveni dose schedul life-long mainten
regimen mechan action spinraza
lack long-term data keep physicians/pati skeptic optimist
page
model eros beyond account competit
spinraza transit patient mainten dose see lumpi
page
spinraza differenti broad label includ peds/adult across sma type
addit differenti label spinraza larger number patient treat spinraza
longer durat treatment safeti data compar competitor
spinraza pt data durat follow-up wherea zolgensma
follow-up data
page
drug label descriptionspinrazazolgensmaapprov datedecemb indic usagebroad label indic treatment sma pediatr adult onsetal sma includ pre-symptomat rout administrationintrathec administr min first dose everi everi monthsone-hr iv infus op administrationpost-treatmentcontinu steroid least month assess liver function weekli month everi week monthswhen result clinical/lab test liver function clean begin steroid taper next day assess platelet troponin-i inject year per maintainenac year instal plan per txblack boxnaacut seriou liver injuri elev aminotransferas biogen inc
think sma franchis may see headwind incom competit
spinraza intrathec administr could limit penetr older children adult
heard kol spinraza oligonucleotid charg larg
make difficult diffus block drainag system fluid brain need
maintain equilibrium fluid need remov displac spinraza
gene therapi use aav eleg solut get brain immune-protect
neuron dont get gene therapi die
page
splice splice gene replacementdrug typeasosmal moleculegen therapydrug load dose mainten dose everi monthsonc dailyon timebodi distributioncn onlysystemicsystemictarget populationapprov typesal typesapprov children annual smn biogen inc
spinraza administr conveni could impact growth
competitor dose appeal oral regimen one-tim gene therapi administr
page
drugspinrazarisdiplamzolgensmacom intrathec fatigu requir intrathec administr facil cost good safeti far enough efficaci safeti data liquid oral formul weight-bas could dififcult administ home liver tox dilut effect reimburs narrow patient popul biogen inc
oral risdiplam could take share spinraza given moa
page
despit near-term approv could take time competit erod spinraza share
expect data experi zolgensma risdiplam take share
spinraza begin beyond
zolgensma approv sma children sever insur compani
reimburs infant month
page
commentdrug classdrugtarget patient ema ema j-nda j-nda filingsmal molecul oral sma type type type therapi iv risdiplamdrug classdrugtarget patient populationphas type part primari efficaci analysessmal molecul oral risdiplamsma type part primari efficaci analysessma type initi datamyostatin inhibitor iv type pk/pd dataphas updat long-term datagen therapi iv zolgensmaphas updat datapre-sym sma type updat datagen therapi intrathec zolgensmasma type updat datapoc studi sma top-line poc studysmal molecul oral firdapsesma type interim month top-line month datasmal molecul oral branaplam type initl datasma type sunfish sma type firefish sma type biogen inc
spinraza approv sma type age group
page
sma typesma type type type type sever common formsymptom onset monthssymptom onset onsetag symptom onset monthsabl sit/stand walkabl walk difficulti never abl sitmuscl weakness/skelet deformitiesmuscl weakness/skelet deform shor tlife expectancyshorten life expectancyclos normal life expect genesmost genesmost gene walk test hine motor milestoneshand held dynamometry/mmthammersmith expand cmapforc vital capacityhand held dynamometry/mmt biomarkerscmapforc vital capac biomark cmap biomark outcom measuresphenotyp inc
efficaci data sma type appear similar across product
page
studyendearfirefish part part intrathec risdiplam oral pill zolgensma iv infus type infantile-onset sma type copi armsspinraza infant cohort low dose cohort high dose part data may first doserang daysmedian age enrol month rang dosingprimari endpointsproport respond improv motor mileston measur hine section efspart safeti toler pk/pdpart primari endpoint proport infant sit without support second month treatment assess gross motor scale bsid-iiiindepend sit ef monthsoutcom interim analysi spinraza vs untreat final analysi spinraza vs untreat summari month risdiplam tx motor mileston month infant infant cohort bcohort high abl sit without support sec infant abl stand support thier weight abl maintain upright head control chop-intend score reach month age experienc surviv without perman ventilationmean age recent visit month average follow-up time monthschop-intend score chop-intend march score increas average one month month gene therapi may intend improv spinraza vs perman ventil spinraza vs controlaft month risdiplam treatment infant aliv event-freeno patient requir perman aliv without perman ventilationdeath/perman ventil spinraza vs infant aliv month fed exclusvi via feed death unrel treatment occur month die respiratori failur dsmb deem unrel requir non-invas bipap ventil day time withdraw commentspulmonari function swallow babi requir tracheostomi reach perman ventil lost abil swallowsurviv biogen inc
data sma type also similar rout administr key differenti uptak
page
part part on-going strongtreatmentspinraza intrathec spinraza intrathec risdiplam oral pill zolgensma intrathec sma type later-onset sma type sma type type copi spinraza untreat later-onsetsma type type sma type sma type first median age rang month dosingprimari endpointschang hfmse score monthsmean hfmse upper limb modul ulm walk test dose-find follow oleprimari endpoint safeti toler pk/pdexploratori efficacypart efficaci safeti select dose placebo-control monthsprimari endpoint mfmprimari efficaci outcom month stand without support chang hfmse baselineoutcom measureschang hfmse month improv motor function vs declin untreatedproport children chang hfmse score hfmse respond vs untreatedchang baselin rulm upper limb function score month spinraza vs untreat ulm score nearli nearli type reach avgerag ulm score max score nearli improv walk abil individu treat spinraza least achiev signific improv abil walk mean hfmse sma type sma type sma type assess nonambul sma type sma type gain abil walk independentlypart baselin pt achiev chang month among among total mfm chang baselin mean sd pt achiev improv sit mean month post-treat mean age score respond month mileston achiev median month f/u month dose crawl pt stand indep stand went ot walk walk assistancecom part efficaci endpoint chang baselin total scorestudi closeout anticip sept result pt exclusionari antibodi titer screen biogen inc
similar efficaci across drug type see eros
howev type smallest share
view type children adult preval higher major opportun
page
spinrazarisdiplamzolgensmaendear studi post treatmentinf dose select confirmatori part zolgensma trial use sit second risdiplam least five second biogen inc
page
biosimilar assumpt account biosimilar enbrel remicad humira
page
samsung collabor expand portfolio access china market provid upsid
believ biosimilar remain underappreci contribut top-line current
biosimilar market await clariti addit biosimilar enter market
samsung bioepi jv privat transact give expans commerci biosimilar lucenti
eylea combin global sale us canada europ japan australia lucenti
patent expir june eylea biosimilar entri could
addit commerci right anti-tnf biosimilar portfolio china
sale segment
page
everi addit biosimilar sale add dcf could off-set sma declin
probabl success
sotp pt
page
page
believ tecfidera like remain intact
page
tecfidera maintain leadership oral market
page
tecfidera ipr remain overhang stock
patent disput direct method treat ms administ specif daili
dosag dmf patent expir februari
buy gilbert win could launch june penultim patent
patent challeng kyle bass coalit afford drug basi
section obvious argument ipr ptab held petition file present
evid refut biib claim magnitud clinic efficaci dose
unexpect thu obviou
decis
decis
oral
page
sinc launch tecfidera sale account ms sale total sale
tecfidera approv march rrm oral market
tecfidera differenti safeti profil oral altern first-dos monitor cardiac
page
win stock could go tecifdera account dcf
tecfidera sale account revenu
win launch gener june could see downsid tp impact
dcf
page
scenariobas bear win patent expir maintain settl win launch gener time gener launchfeb gener entri impact impact dcf biogen inc
page
recal tauopathi character tau aggreg
role tau microtubule-associ protein mapt bind stabil microtubul
especi neuron axon
pathogen tau diseas state assum sever featur includ aberr phosphoryl
posttransl modif truncat aggreg oligom larger insolubl
tauopathi progress neurodegen disord character tau aggreg
tauopathi includ ad psp corticobas syndrom frontotempor dementia chronic traumat
encephalopathi diseas share presenc tau differ distribut natur tau
page
tau mediat diseas affect peopl ad ftd us
page
anim model support reduct tau biomark prevent tau patholog
role tau microtubule-associ protein mapt bind stabil microtubul
especi neuron axon tau protein typic unfold highli solubl found neuron
cell pathogen tau protein thought contribut certain tauopathi
pathogen tau diseas state assum sever featur includ aberr phosphoryl posttransl
modif truncat aggreg oligom larger insolubl filament
hallmark featur tauopathi abnorm tau lead accumul toxic neurofibrillari tangl insid
nerv cell bodi brain
transgen mous model reduct tau prevent hippocamp neuron loss prevent
tau patholog lead advers phenotyp
page
tauopathi competit heat overlap ad psp
ad frontotempor
show efficaci discontinu
psp data expect
data expect
enrol complet aug
page
pipelin focu tau tauopathi earli stage psp expect
common genet variant mapt gene make tau protein associ neurolog
disord ad parkinson frontotempor dementia recent studi shown genet
link mapt al rais possibl al tau-medi diseas
psp tauopathi character accumul neurofibrillari tangl tuft
asid anti-tau psp ad also
anti-tau aso ad
alpha-synuclein monoclon antibodi parkinson diseas phase data
aso al phase data expect
tau
phase final readout psp expect
phase data expect
valor phase data expect
phase data expect
phase data expect
page
posit psp data could repres upsid give credit yet
psp highli correl aggreg tau isoform predominantli subcort region
midbrain/bas ganglia wherea tau isoform observ ad
psp tau aggreg found neuron glia psp patient earlier onset shorter durat
diseas compar cbd ad
believ anti-tau monoclon antibodi work block extracellular tau reduc tau
spread patholog brain
phase data show reduct csf free etau
potenti file data posit
note nr announc discontinu phase psp
futil analysi show show efficaci psp patient ad studi remain
page
aso design select reduc mapt ad ftd
ad ftd form dementia character predomin memori impair behavior
chang result progress inabl perform daili task independ eventu death
accumul patholog tau ad patholog correl cognit declin ad ftd
typic occur follow accumul neuron protein includ tau
mapt tau protein contributor caus certain neurodegen diseas character
abnorm tau protein neuron non-neuron cell brain
mapt aso revers patholog diseas mous model reduc tau
phase on-going patient ad
phase studi plan mapt-ftd
page
target alpha-synuclein patholog pd
page
alpha-synuclein monoclon antibodi parkinson diseas phase data
develop neurimmun platform adu monoclon antibodi target
extracellular -synuclein parkinson diseas
pd second common neurodegen disord preval patient across
avail treatment slow progress
psp-tau case tau patholog month ad/cbd psp-tau seed tau aggreg
neuron subtyp hippocampu ad-tau
aggreg misfold -synuclein degener nigrostriat dopaminerg neuron
hallmark patholog pd
-synuclein major compon lewi bodies/neurit
genet data famili pd show -synuclein could play causal role pd diseas
pathogenesi misfold -synuclein aggreg insid neuron associ oxid stress
disrupt axon transport synapt dysfunct also spread neighbor
symptom includ rest tremor muscular rigid bradykinesia postur instabl motor
symptom due dopamin loss neuron brain non-motor manifest includ
sensori problem sleep disord neuropsychiatr problem dementia averag age onset
late earli
page
phase parkinson diseas goal reduc spread tau
psp-tau case tau patholog month ad/cbd psp-tau seed tau aggreg
neuron subtyp hippocampu ad-tau
murin model observ reduc spread synuclein patholog
brain unlik ad protein aggreg predominantli cortex pd distribut
subcort area brain
psp seed tau ad earlier time point neuron tau aggreg observ
month induc glial tau aggreg astrocyt oligodendrocyt month show fast rate
glial tau path format psp/cbd ps/cbd show propag tau inclus cortic
region ad-tau
page
page
companyproductdescriptiontherapuet gosunaremab mab target tau n-terminu pspphase final readout psp expect mabcl slephas studi cle sle expect target -synucleinparkinson diseasephas data expect tofersen mrnaalsvalor phase data expect fiber neuropathyphas data expect late gosunaremab mab target taualzheim diseasephas anti-tau mab c-terminusalzheim diseasephas ionis-mapt aso target tau mrna target taualzheim diseasephas target inhibitorsporad ligand trapsmaphas biogen inc
al build upon biib neuromuscular disord franchis overlap als/sma center
build neuromuscular disord spinraza leverag commerci footprint sma
overlap al center sma center us/eu
page
aim least al program across famili sporad diseas
al progress fatal neurodegen diseas death within diagnosi averag
age symptom onset al character progress muscl weak lead
respiratori failur death
character cytoplasm inclus motor neuron
standard riluzol edaravon approv al treatment us howev
disease-modifi treatment al
preval al newli diagnos case year across
famili al caus mutat other
al first identifi genet caus al
common genet caus al
form al
page
tofersen aso degrad target rna transcript
tofersen al al tau ad tauopathi
collabor
aso induc rnase h-mediat degrad target rna transcript
page
could gener combin peak revenu annual
page
tofersen reduc famili al
tofersen aso design reduc product superoxid dismutas
best understood genet caus famili al
mutant gene respons toxic gain function lead rapid progress loss motor
neuron patient lead muscl weak loss movement difficult breath
swallow eventu death
current treatment option limit drug current avail significantli slow diseas
ppl diagnos al incid ms
riluzol approv drug extend life month
al genet studi provid select target popul
common caus famili al
famili account al
page
tofersen reduc concentr csf
poc sever anim model show reduct improv motor function surviv
anim model concentr csf substanti reduc higher tofersen
given tofersen reduct protein spinal fluid compar
receiv pbo also score better test measur breath capac
muscl strength well ppl function activ compar pbo group
page
phase interim data show slow clinic function respiratori function declin
phase primari endpoint alsfrs-r score valid rate instrument monitor progress
disabl patient al
page
phase valor data al expect
primari safety/toler pk measur tofersen plasma/csf
secondari chang baselin csf level protein
exploratori endpoint includ chang form baselin clinic function
tofersen placebo
primari alsfrs-r score valid rate instrument monitor
progress disabl patient al
page
select target mutant expans transcript reduc risk toxic
hexanucleotid ggggcc repeat expans caus toxic gain function lead rapid
progress motor neuron loss common caus als/ftd aso design
reduc product mutat chromosom open read frame gene
preclin studi show select reduct toxic rna aso
demonstr reduc behavior deficit sustain
minor transcript gene contain repeat approach allow
select lower diseas associ transcript preserv major rna
select import homozyg delet shown induc immune-rel
patholog preclin model
bind
sequenc upstream
hexanucleotid
page
expect data on-going phase studi potenti launch
aso design reduc product mutat chromosom open read frame
mutant gene result inherit form al lead known genet caus
al substanti evid shown mutat respons toxic gain function
repeat expans lead rapid progress loss motor neuron repeat rna
sequest rna-bind protein inhibit nucleocytoplasm transport
target transcript contain hexanucleotid repeat expans degrad
biomark target engag within incorpor measur well
exploratori efficaci measur on-going phase studi data expect
page
tofersen aso degrad target rna transcript
page
strh research compani report
page
incom statement biogen sale lingo sale product revenu revenu intang non- profit oper expens itemsnet interest incom pre-tax incom provis attrib non-control net ep per base growthamort acquir non recur net incom ep per share outstand share outstand biogen inc
page
balanc sheet collater loan securities- current total current asset market goodwill- non current total asset liabil sharehold tax payables- accru current portion note total current liabil note long term defer tax lt total liabil addit paid retain total sharehold total liabil sharehold sourc compani report strh estim biogen inc
page
statement operationsnet non-oper itemsdepreci current accru current excl note oper investingproce sale manufactur sale matur market market consider invest financingdebt financ ce ce market secur compani report strh estim biogen inc
manag compens align well sharehold interest
overal compens plan appear line sharehold interest name execut offic
elig earn incent bonu base individu perform goal well corpor
goal relat product develop advanc clinic studi compens
execut structur around achiev corpor goal mileston year
base subject object perform goal determin board director
page
mr vounatso join year career merck
prior presid primari busi line merck custom centric
prior manag posit ciba-geigi
mr vounatso receiv mba hec school manag pari
mr capello cfo serv execut committe sinc decemb
prior cfo beacon health option
prior cfo ortho clinic diagnost boston scientif corpor
mr capello receiv mba harvard busi school
dr sandrock serv sinc join compani
held sever senior execut posit
dr sandrock receiv md harvard medic school phd harvard univers
page
inc biopharmaceut compani engag discov develop
deliv therapi neurolog neurodegen diseas offer
tecfidera avonex plegridi tysarbi zinbryta fampyra treatment multipl
sclerosi spinraza treatment spinal muscular atrophi fumaderm
treatment sever plaqu psoriasi compani found charl weissmann
heinz schaller kenneth murray walter gilbert phillip allen sharp
headquart cambridg
page
inc biopharmaceut compani engag discov develop deliv
therapi neurolog neurodegen diseas offer tecfidera avonex plegridi
tysarbi zinbryta fampyra treatment multipl sclerosi spinraza treatment
spinal muscular atrophi fumaderm treatment sever plaqu psoriasi compani
found charl weissmann heinz schaller kenneth murray walter gilbert phillip allen
sharp headquart cambridg
surpris announc fda aducanumab phase data thesi hing
aducanumab obtain fda approv pipelin tauopathi al part
earli give credit pipelin ad wait data biogen
grow biosimilar pipelin expans china market samsung bioepi
collabor think street underappreci abil grow anoth segment beyond ms
spinraza sma rate buy pt
valuat risk
target price deriv dcf assum ms sale declin
spinraza peak sale adjust ad sale model
dcf termin growth rate discount rate instead matur
biotech compani account potenti commerci execut ad termin valu
arriv tp
risk includ on-going fda reject aducanumab bla file ad competit sma
compani mention note
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
